Next Article in Journal
Association of Kinesiophobia with Catastrophism and Sensitization-Associated Symptoms in COVID-19 Survivors with Post-COVID Pain
Next Article in Special Issue
Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review
Previous Article in Journal
Comparison of MT-PCR with Quantitative PCR for Human Bocavirus in Respiratory Samples with Multiple Respiratory Viruses Detection
Previous Article in Special Issue
Current Perspectives on Periodontitis in Systemic Sclerosis: Associative Relationships, Pathogenic Links, and Best Practices
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 13
Issue 5
10.3390/diagnostics13050848
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Clinical Significance of Salusins in Systemic Sclerosis—A Cross-Sectional Study

by
Joanna Nowaczyk
1,
Leszek Blicharz
1,
Michał Zawistowski
1,
Mariusz Sikora
2,
Michał Zaremba
1,
Joanna Czuwara
1,* and
Lidia Rudnicka
1
1
Department of Dermatology, Medical University of Warsaw, 02-091 Warsaw, Poland
2
National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Diagnostics 2023, 13(5), 848; https://doi.org/10.3390/diagnostics13050848
Submission received: 31 January 2023 / Revised: 14 February 2023 / Accepted: 21 February 2023 / Published: 23 February 2023
(This article belongs to the Special Issue Recent Advances in Diagnosis and Management of Systemic Sclerosis)
Browse Figures
Versions Notes

Abstract

:
Background: Systemic sclerosis (SSc) is a connective tissue disease manifesting with progressive fibrosis of the skin and internal organs. Its pathogenesis is strictly associated with vascular disfunction and damage. Salusin-α and salusin-β, endogenous peptides regulating secretion of pro-inflammatory cytokines and vascular smooth muscle proliferation, may potentially play a role in SSc pathogenesis. Objectives: The aim of this study was to assess the concentration of salusins in sera of patients with SSc and healthy controls and to evaluate correlations between the salusins levels and selected clinical parameters within the study group. Materials and methods: 48 patients with SSc (44 women; mean age, 56.4, standard deviation, 11.4) and 25 adult healthy volunteers (25 women; mean age, 55.2, standard deviation, 11.2) were enrolled. All patients with SSc were treated with vasodilators and twenty-seven of them (56%) also received immunosuppressive therapy. Results: Circulating salusin-α was significantly elevated in patients with SSc in comparison to healthy controls (U = 350.5, p = 0.004). Patients with SSc receiving immunosuppression had higher serum salusin-α concentrations compared with those without immunosuppressive therapy (U = 176.0, p = 0.026). No correlation was observed between salusins concentrations and skin or internal organ involvement parameters. Conclusions: Salusin-α, a bioactive peptide mitigating the endothelial disfunction, was elevated in patients with systemic sclerosis receiving vasodilators and immunosuppressants. Increased salusin-α concertation may be associated with the initiation of atheroprotective processes in patients with SSc managed pharmacologically, which requires verification in future studies.

1. Introduction

Systemic sclerosis is an autoimmune connective tissue disease characterized by progressive fibrosis of the skin and internal organs. Microvascular changes with endothelial disfunction, epigenetics, and complex autoimmune responses are the major factors contributing to the development of the disease [1]. In systemic sclerosis, vascular damage plays a pivotal role in the pathogenesis of tissue fibrosis; therefore, identifying markers of endothelial disfunction is crucial to help optimize patients assessments and to develop novel treatment methods aimed at mitigating progressive fibrosis [2,3,4,5]. One of the therapeutic aims is to stabilize the progression of microangiopathy, i.e., the loss of capillaries over time, which correlates with the course of disease [6]. Despite that circulating antibodies, such as Scl-70 (anti-topoisomerase I), are known to be associated with disease prognosis [7], limited evidence is available in regard to reliable therapeutic biomarkers in systemic sclerosis [8]. Therefore, researchers are constantly investigating new molecules of potential significance in the pathogenesis of the disease.

1.1. Bioactive Peptide Biomarkers-Salusin-α and Salusin-β

Among the candidates to be considered as systemic sclerosis biomarkers are salusins. These are two bioactive peptides, named salusin-α and salusin-β, which are derived from the TOR2A precursor, preprosalusin [9,10]. Salusins are produced in kidneys, central nervous system, and cardiovascular system [9,10]. In vitro studies have shown that salusin-α has anti-inflammatory properties manifested by the ability to decrease the expression of pro-inflammatory interleukins, i.e., IL-6, IL-8, and IL-18 [11]. Salusin-β promotes vascular remodeling as a result of various processes, involving vascular smooth muscle cell proliferation (the cAMP–PKA–EGFR-CREB/ERK pathway), fibrosis (the TGF-β1-Smad pathway), the activation of NF-κB pathway with reactive oxygen species (ROS) production, and increased mRNA expression of collagen I, collagen III, fibronectin, TGF-β1, and connective tissue growth factor [12,13,14,15,16].

1.2. Salusins and the Vascular Tone Regulation

Due to its involvement in vascular homeostasis pathways, salusins may play a role in fibroproliferative vasculopathy in systemic sclerosis. One of the important factors in vascular tone regulation is disbalance between nitric oxide and endotelin-1 (ET-1), both secreted by the endothelium, which may be relevant for the progression of endothelial disfunction in patients with systemic sclerosis [5,17]. A vasoconstrictor peptide, endothelin-1, modulates the vascular tone to maintain the proper vascular homeostasis by the mediation of smooth muscle vasoconstriction (through the ETA receptor) and stimulation of nitric oxide secretion (through the ETB receptor) [5,18,19]. Salusin-β was found to attenuate vasodilation in the mice model of hypertension by activating reactive oxygen species and inhibiting nitric oxide release [20,21]. In rats with induced pulmonary arterial hypertension, salusin-β inhibition contributed to decreased macrophage infiltration and pro-inflammatory cytokine expression in the lungs [22].

1.3. Salusins and the Endothelial Disfunction

The dysregulation of endothelin-1/nitric oxide ratio may also contribute to cardiovascular disorders associated with endothelial disfunction, such as atherosclerosis and arterial hypertension [18]. In the process of tissue fibrosis, vascular myofibroblasts may undergo cellular differentiation referred to as endothelial-to-mesenchymal transition, which is a conversion of the cell phenotype from endothelium markers into mesenchymal cell markers [5]. In a murine model, salusin-α injections were associated with decreased TNFα and IL-6 levels, arterial plaque formation, and a decreased presence of foam cells, while salusin-β was associated with increased TNFα and IL-6 concentrations, atherogenesis, and foam cell formation [14,23]. The impact of salusin-β on arterial plaque formation is related to the NF-κB pathway; however, salusin-α is not involved in this pathway [11,14,24]. Salusin-α mitigates atherosclerosis through the inhibition of vascular smooth muscle cells proliferation and migration mediated by the Akt/mTOR pathway [25].

2. Materials and Methods

A retrospective single-center pilot cross-sectional study was conducted at the Department of Dermatology, Medical University of Warsaw, Poland. Its results were reported in line with the strengthening the reporting of observational studies in epidemiology (STROBE) statement [26]. The primary aim of this study was to compare the concentrations of salusin-α and salusin-β in sera of patients with systemic sclerosis and healthy controls. Furthermore, exploratory analyses were performed in the systemic sclerosis group, only to find potential associations between serum salusin-α and salusin-β levels and selected clinical parameters reflecting skin or internal organ involvement in the disease.

2.1. Ethics

The study protocol was approved by the institutional review board, the Ethics Committee at the Medical University of Warsaw (the study protocol approval number KB/149/2020). The study was completed in accordance with the ethical standards of the 1964 Helsinki declaration with future revisions and international conference on harmonization good clinical practice guidelines.

2.2. Study Group and Data Collection

Adult patients with systemic sclerosis (diffuse or localized) consecutively admitted between May 2019 and July 2021 to the Department of Dermatology, Medical University of Warsaw, Poland were considered eligible for inclusion in this study. Patients were undergoing their treatment in accordance with the current recommendations of the Polish Dermatological Society [27]. Only individuals who were electively admitted in order to receive intravenous vasodilative treatment (alprostadil, epoprostenol, or sulodexide) and who signed an informed consent form were enrolled. Exclusion criteria were active cancer, infection, pregnancy, chronic systemic treatment with nonsteroidal anti-inflammatory drugs or corticosteroids, and any modification of systemic therapy within the preceding month.
In this study, a review of inpatient medical records was the main source of demographical and clinical data. All participants had their blood samples collected for further evaluation, including salusin-α and salusin-β concentration assessment. Other tests were performed as part of their routine clinical assessment. For patients in the experimental (systemic sclerosis) group, demographic information and medical details were collected, including current treatment and comorbidities. Findings in the recent imaging examinations were retrieved, such as high-resolution computed tomography (HRCT) of the thorax performed within the last year, diffusion lung capacity for carbon monoxide (DLCO) value assessed within the last year, and the esophageal X-ray with contrast from the previous three years. Complete blood count test results (including the counts of lymphocytes and neutrophils used to calculate the neutrophil-to-lymphocyte ratio; NLR), serum creatinine levels (used to calculate estimated glomerular filtration rate with the Chronic Kidney Disease Epidemiology Collaboration 2021 equation [28,29]), erythrocyte sedimentation rate (ESR) values, and C-reactive protein (CRP) concentrations were determined in the samples collected on the same day as the samples for salusins concentration assessment. Occurrence of fingertip erosions and the severity of skin thickening according to the modified Rodnan skin score (mRSS) [30] were assessed at the time of elective admission to the ward.
The control group consisted of healthy volunteers, from whom only demographic details (age and BMI) were collected apart from the blood samples used for the determination of their salusin-α and salusin-β concentrations. Individuals from the control group were not diagnosed with metabolic diseases and did not have past or present history of glucocorticoids treatment or other immunosuppressive medications.

2.3. Salusin-α and Salusin-β Concentrations Measurement

Salusin-α and salusin-β levels were analyzed at the Laboratory of Immunodermatology, Department of Dermatology, Medical University of Warsaw, Poland. Enzyme-linked immunosorbent assay kits (Bioassay Technology Laboratory, Shanghai, China) were used as per the manufacturer’s protocol.

2.4. Statistical Analysis

For the purpose of descriptive analysis, continuous variables were evaluated using histograms, the Shapiro–Wilk test and Q-Q plot analysis. Normally distributed variables were reported using means and standard deviations, while non-normally distributed ones were summarized with medians and ranges. Qualitative variables were described using the numbers of events and frequencies. To compare differences in continuous variables between the groups, Student’s t-test for normally distributed or Mann–Whitney U test for non-normally distributed parameters were used. The assumption of equal variances was verified with the Levene’s test. For the comparison of categorical variables with all expected values of at least 5, the Chi-squared test was utilized. Otherwise, the Fisher’s exact test was applied. Simple linear regression was used to assess the relationship between serum salusin-α and salusin-β concentrations in patients with systemic sclerosis, healthy volunteers and both groups combined. To find correlations or associations between preselected variables, Spearman’s ranked correlation and Gaussian graphical model analysis were used (as part of the exploratory analysis). All instances of missing data were assumed to be missing completely at random and deleted pairwise. No data were imputed. Two-sided p values < 0.05 were considered statistically significant. No correction for multiple comparisons was applied. All calculations were completed and plots created using the psych [31], the qgraph [32], the seolmatrix [33], and the ppcor [34] modules in the statistical software jamovi 2.3.21 (The jamovi project, 2022) [35,36].

3. Results

Forty-eight patients with systemic sclerosis (44 women; mean age, 56.4 years, standard deviation, 11.4) and twenty-five healthy volunteers (25 women; mean age, 55.2 years, standard deviation, 11.2; mean body mass index [BMI], 23.6, standard deviation, 4.2) were enrolled in this study. Detailed characteristics of the study group are presented in Table 1. There were no statistically significant differences in sex (p = 0.292), age (t[71] = 0.44, p = 0.664), and BMI (t[68] = 1.29, p = 0.201) between the experimental and control groups.

3.1. Salusin-α and Salusin-β Concentrations

Salusin-α was significantly elevated in patients with systemic sclerosis when compared with healthy volunteers (181.85 [85.66–951.80] vs. 120.70 [24.03–362.40] pg/mL; U = 350.5; p = 0.004; Table 2, Figure 1). No such association was detected for salusin-β (173.70 [113.70–3288.00] vs. 186.30 [120.30–773.50]; U = 550.0; p = 0.662). Salusin-α and β concentrations were strongly correlated with each other (F[1, 70] = 94.56, p < 0.001, R2 = 0.57, Figure 2).

3.2. Anti-Topoisomerase I (Scl-70) and Anti-Centromere (ACA) Antibodies

No statistically significant associations were detected between the presence of Scl-70 (anti-topoisomerase I) or ACA and salusin-α or β concentrations (for salusin-α and Scl-70, 174.5 [97.4–951.8] vs. 186.7 [85.7–525.1] pg/mL, U = 264.5, p = 0.815; for salusin-α and ACA, 180.0 [128.2–823.0] vs. 187.2 [85.7–951.8] pg/mL, U = 254.5, p = 0.812; for salusin-β and Scl-70, 160.0 [116.9–1840.0] vs. 178.4 [113.7–3288.0] pg/mL, U = 234, p = 0.516; for salusin-β and ACA, 170.3 [113.7–1092.0] vs. 174.5 [121.2–3288.0] pg/mL, U = 213.5, p = 0.343).

3.3. Skin and Internal Organ Involvement

A moderately strong negative correlation was found between serum creatinine levels and the concentrations of salusin-α (Spearman’s ρ = −0.32, p = 0.035). Similar results were obtained for salusin-β (Spearman’s ρ = −0.37, p = 0.015). No statistically significant correlations or associations were detected between salusins concentrations and parameters reflecting disease involvement of skin or other organs in systemic sclerosis (Table 3, Figure 3).

3.4. Comorbidities

Diabetic patients had significantly decreased salusin-β levels (123.95 [113.7–134.2] vs. 174.5 [116.9–3288.0] pg/mL, U = 5.0; p = 0.037); however, the subgroup was represented by two patients only. No such observation was made for salusin-α (151.35 [128.2–174.5] vs. 187.0 [85.7–951.8] pg/mL, U = 19.0, p = 0.172). No correlations were observed between the presence of thyroid disease (either hypo- or hyperthyroidism) and salusin-α (174.7 [97.4–951.8] vs. 182.2 [85.7–823.0] pg/mL, U = 185.0, p = 0.659) or β concentrations (174.5 [121.8–1192.0] vs. 167.9 [113.7–3288.0] pg/mL, U = 185.0, p = 0.753). No statistically significant association was detected when the occurrence of other autoimmune disorders (such as lichen planus, vulvar lichen sclerosus, cicatricial alopecia, Sjögren syndrome, antiphospholipid syndrome, and primary sclerosing cholangitis) was compared with salusin-α (204.5 [152.6–823.0] vs. 180.8 [85.7–951.8] pg/mL, U = 162.0, p = 0.372) or salusin-β serum levels (192.2 [134.2–1840.0] vs. 167.9 [113.7–3288.0] pg/mL, U = 164.0, p = 0.400).

3.5. Treatment

Selected patients were treated with single-drug immunosuppression (n = 27) together with oral medications of rheologic properties (pentoxifylline, sildenafil, or oral sulodexide in various combinations) on a daily basis or intravenous ones (alprostadil, epoprostenol, or sulodexide) while admitted to the hospital. Immunosuppressive medications used by the patients included mycophenolate mofetil (n = 16), methotrexate (n = 10), and cyclophosphamide (n = 1). Patients not receiving immunosuppression therapy, were prescribed with rheologic medications only. Patients undergoing immunosuppressive treatment had statistically significantly higher salusin-α concentrations than those on rheologic therapy only (235.3 [133.5–951.8] vs. 174.5 [85.7–525.1] pg/mL, U = 176.0; p = 0.026, Table 4, Figure 4). No similar associations were found between treatment modalities and salusin-β concentrations (281.2 [121.2–2399.0] vs. 156.6 [113.7–3288.0] pg/mL, U = 191.0; p = 0.081).

4. Discussion

In our study, we compared the concentrations of salusin-α and salsin-β between the groups of patients with systemic sclerosis and healthy volunteers. We found statistically significant elevation of salusin-α in individuals with systemic sclerosis (p = 0.004; Figure 1, Table 2). Such a difference was not detected in regard to salusin-β. Furthermore, we showed that both salusins were strongly correlated with each other (p < 0.001, R2 = 0.57), which is consistent with their common origin from one precursor peptide. As expected, their concentrations were lower and better linearly correlated in healthy volunteers (p < 0.001; R2 = 0.93) than in patients with systemic sclerosis (p < 0.001; R2 = 0.55), in whom it is hypothesized that these mediators may play a role in disease pathogenesis leading to their higher concentrations and noticeable balance disturbances.
A moderately strong negative association between serum creatinine and salusin-α (Spearman’s ρ = −0.32, p = 0.035) and β (Spearman’s ρ = −0.37, p = 0.015) was reported; however, a potential clinical association could not be identified. This finding may be related to renal function of the patients, as salusins are also produced in the kidneys. Nevertheless, none of the patients had a documented history of current acute kidney injury (AKI) or end-stage renal disease (ESRD).
We also noted that a statistically significant correlation was present between salusin-α levels and the therapy used. Patients undergoing immunosuppressive treatment had significantly higher salusin-α concentrations than those treated with vasodilators only (p = 0.026; Figure 4, Table 4). This phenomenon associated with pharmacologic treatment has not been observed in previous studies on salusins. Furthermore, no previous studies analyzing both salusin-α and salusin-β concentrations in systemic sclerosis were published to date.
As potential peptide biomarkers, salusins are being studied since 2003 [9]. Despite that, they are not commonly measured in patients beyond research as their role and usefulness in clinical practice has not yet been fully established. Decreased salusin-α and elevated salusin-β reflecting endothelial disfunction were primarily observed in patients with chronic kidney disease and cardiovascular diseases, such as coronary artery disease, atherosclerosis, and hypertension [10,23,37,38]. In a recent study, salusin-α was found to be negatively correlated with the cardiovascular risk score of the newly validated systematic coronary risk estimation 2 (SCORE2) algorithm [39,40]. Some reports indicate the role of salusins in diseases of dermatologic and/or rheumatologic origin.

4.1. Salusin Concentration in the Skin and Connective Tissue Diseases

The literature regarding the role of salusins in patients with dermatological and rheumatological disorders is inconsistent. In systemic sclerosis and systemic lupus erythematosus (SLE), Koca et al. [41] observed decreased salusin-α concentrations. Nevertheless, after adjusting for age, no correlation was identified between salusin-α concentrations and disease activity, intima media thickness, or TNFα and IL-6 levels. Erden et al. [42,43] also observed decreased salusin-α concentrations in psoriasis and Behçet disease. Importantly, salusin-α was even lower in patients with metabolic syndrome and, regarding psoriasis, also in individuals with higher psoriasis area severity index (PASI) score.
Elevated salusin-α concentrations were reported by Ozgen et al. [44] in a group of patients with rheumatoid arthritis and Behçet’s disease, which were also positively correlated with the intima media thickness (after adjusting for age, gender, BMI, and current treatment). Kobak et al. [45] also observed significantly elevated salusin-α concentrations in psoriatic arthritis, which positively correlated with CRP values and arthritis.
As previously mentioned, salusin functions and concentrations were well-investigated in mice models and in vitro studies. Nonetheless, the reports in skin and connective tissue diseases involving humans stay inconclusive due to the complexity of occurring processes and misidentified confounders such as pharmacotherapy and comorbidities [46].

4.2. The Use of Corticosteroid Therapy

An important factor not considered in previously discussed reports on salusins was the frequent use of long-term systemic corticosteroid therapy, which was an exclusion criterion in our study. Long-term corticosteroid intake is considered to be a strong confounding factor due to possible influence on various physiological and inflammatory processes; therefore, the association between the biomarker concentration and the treatment used may be potentially affected. In our study, patients receiving oral treatment with corticosteroids as well as other factors alleviating immune responses (such as oral non-steroidal anti-inflammatory drugs or pregnancy) were not enrolled due to potential interference with inflammatory parameters (e.g., CRP and lymphocyte count) and, consequently, biomarker concentrations.
Erden et al. [43] showed decreased salusin-α levels in Behçet disease; however, 52% of patients were undergoing treatment with corticosteroids together with non-corticosteroid immunosuppressants such as azathioprine, colchicine, and cyclosporine. Koca et al. [41], who observed no statistically significant decrease of salusin-α in systemic sclerosis and systemic lupus erythematosus, indicated that 95% of the patients with systemic lupus erythematosus and 36% of patients with systemic sclerosis were receiving systemic corticosteroids. Kobak et al. [45] reported statistically significant elevated salusin-α levels in psoriatic arthritis; however, 15% of patients received low-dose corticosteroids and others were treated with methotrexate, biologic agents, or did not receive any therapy.
In Behçet disease, Ozgen et al. [44] performed a separate analysis regarding the treatment type and observed some statistically significant correlations. In that study, salusin-α was significantly elevated in patients receiving systemic corticosteroids (corresponding to 30.6% of the experimental group), while salusin-α was decreased in those treated with azathioprine (accounting for 22.2% of the treatment group) [44].

4.3. Non-Corticosteroid Immunosuppressive Medications

In our study, we observed a statistically significant correlation between immunosuppression and antiatherogenic salusin-α–patients receiving immunosuppressive medications with higher salusin-α concentrations. The anti-inflammatory and atheroprotective properties of selected non-corticosteroid immunosuppressive agents were reported in the literature [47].
The immunosuppressive medication with the widely proven impact on endothelial disfunction is methotrexate [48,49]. Methotrexate was shown to attenuate the secretion of proinflammatory mediators and monocyte adhesion in mice cells via an adenosine-related pathway [50,51]. In result, the processes of vascular inflammation involving T-cell mediated cytotoxicity, neutrophil oxidative burst, and NF-κB pathways associated with reactive oxygen species production are inhibited [48]. In a 12-week open-label study on patients with rheumatoid arthritis, methotrexate was also reported to enhance adenosine-induced vasodilation (determined by forearm blood flow measurement and adenosine deaminase activity in erythrocytes and lymphocytes) [52]. In another study involving patients treated with methotrexate for rheumatoid arthritis, a clinical difference was shown in carotid intima media thickness [53,54], while other studies did not shown any significant changes in this parameter or altered aortic distensibility [55,56].
Furthermore, complex anti-atherosclerotic and anti-inflammatory properties of mycophenolate mofetil metabolite were described [57], i.e., via limiting the in vitro adhesion of mononuclear leukocytes to endothelial cells [58] and inhibiting fibroblast nitric oxide synthase [59,60]. Mycophenolate mofetil also inhibits TNF-α-induced NF-kB activation, which results in attenuated reactive oxygen species production [61]. Nevertheless, one study on patients with systemic lupus erythematosus has not shown inhibition of atherogenesis and indicated progression of intima media thickness over a 2-year period despite mycophenolate mofetil therapy in various dosages [62].
Brief reports are available regarding the atheroprotective properties of cyclophosphamide. In a low dose, cyclophosphamide was shown to inhibit atherosclerosis in murine model by a reduction of Th1 response and monocyte/macrophage migration to the plaque [63].
It can be hypothesized that vasodilative and anti-inflammatory processes inducted by non-corticosteroid immunosuppressive agents could possibly induce salusin-α production and, in result, enhance other processes against endothelial disfunction in systemic sclerosis. Nonetheless, the association between immunosuppression and endothelial function is not confirmed due to existing research gaps and the complexity of autoimmune processes in humans in comparison to in vitro studies [46].

5. Study Limitations

The main limitation of this study is a small sample size, which confines the ability to identify all true correlations and results in the small number of some secondary endpoints (e.g., only one patient had pulmonary hypertension). No significant correlations were detected between salusin-β levels and other preselected parameters, which may also result from small sample size or previously reported fluctuating concentrations due to the adherence of salusin-β to plastic laboratory tubes [64]. This study had a retrospective exploratory character, which results in the presence of missing data and does not allow for drawing causative inference.

6. Conclusions

Salusins are circulating peptide biomarkers of endothelial disfunction. High serum salusin-α is a prospective marker of the preserved function of endothelial cells, while high serum salusin-β indicates the occurrence of vascular remodeling. To our knowledge, this is the first study investigating concentrations of both salusin-α and salusin-β in systemic sclerosis.
In this study, elevated salusin-α concentrations were observed in patients with systemic sclerosis compared with healthy individuals (p = 0.004). Furthermore, systemic sclerosis patients receiving immunosuppressive treatment had significantly higher salusin-α concentrations than those treated with rheologic medications only (p = 0.026). Both salusins levels were statistically significantly correlated with serum creatinine concentrations.
Due to the limited evidence regarding salusins in the skin and connective tissue diseases, additional research is needed to fully understand the hypothesized positive impact of salusin-α in pharmacologically treated patients with systemic sclerosis.

Author Contributions

Conceptualization, J.N. and M.S.; methodology, J.N., M.Z. (Michał Zawistowski), M.S. and J.C.; software, M.Z. (Michał Zawistowski); validation, L.B. and J.C.; formal analysis, J.N., M.Z. (Michał Zawistowski) and M.Z. (Michał Zaremba); investigation, J.N.; resources, L.B., J.C., M.Z. (Michał Zaremba) and L.R.; data curation, J.N.; writing—original draft preparation, J.N.; writing—review and editing, L.B., M.Z. (Michał Zawistowski), J.C. and L.R.; visualization, M.Z. (Michał Zawistowski); supervision, L.B., J.C. and L.R.; project administration, J.N.; funding acquisition, J.N. and M.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Medical University of Warsaw (grant number 1M4/2/M/MG/N/20).

Institutional Review Board Statement

This study was approved by the institutional research board (Ethics Committee at the Medical University of Warsaw; study protocol approval number KB/149/2020) and was performed in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not Applicable.

Conflicts of Interest

The funders had no role in the design of the study; in the collection, analyses, and interpretation of data; in the writing of the manuscript; and in the decision to publish the results.M. Zawistowski is an AstraZeneca employee.

References

  1. Cutolo, M.; Soldano, S.; Smith, V. Pathophysiology of systemic sclerosis: Current understanding and new insights. Expert Rev. Clin. Immunol. 2019, 15, 753–764. [Google Scholar] [CrossRef] [Green Version]
  2. Zanin-Silva, D.C.; Santana-Gonçalves, M.; Kawashima-Vasconcelos, M.Y.; Oliveira, M.C. Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies. Front. Med. 2021, 8, 788250. [Google Scholar] [CrossRef]
  3. Affandi, A.J.; Radstake, T.R.D.J.; Marut, W. Update on biomarkers in systemic sclerosis: Tools for diagnosis and treatment. Semin. Immunopathol. 2015, 37, 475–487. [Google Scholar] [CrossRef] [Green Version]
  4. D’Oria, M.; Gandin, I.; Riccardo, P.; Hughes, M.; Lepidi, S.; Salton, F.; Confalonieri, P.; Confalonieri, M.; Tavano, S.; Ruaro, B. Correlation between Microvascular Damage and Internal Organ Involvement in Scleroderma: Focus on Lung Damage and Endothelial Dysfunction. Diagn. Basel Switz. 2022, 13, 55. [Google Scholar] [CrossRef]
  5. Mostmans, Y.; Cutolo, M.; Giddelo, C.; Decuman, S.; Melsens, K.; Declercq, H.; Vandecasteele, E.; De Keyser, F.; Distler, O.; Gutermuth, J.; et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review. Autoimmun. Rev. 2017, 16, 774–786. [Google Scholar] [CrossRef]
  6. Smith, V.; Pizzorni, C.; Riccieri, V.; Decuman, S.; Brusselle, G.; De Pauw, M.; Deschepper, E.; Piette, Y.; Ruaro, B.; Sulli, A.; et al. Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study. J. Rheumatol. 2016, 43, 995–996. [Google Scholar] [CrossRef] [Green Version]
  7. Tieu, A.; Chaigne, B.; Dunogué, B.; Dion, J.; Régent, A.; Casadevall, M.; Cohen, P.; Legendre, P.; Terrier, B.; Costedoat-Chalumeau, N.; et al. Autoantibodies versus Skin Fibrosis Extent in Systemic Sclerosis: A Case-Control Study of Inverted Phenotypes. Diagnostics 2022, 12, 1067. [Google Scholar] [CrossRef]
  8. Zhang, L.; Wu, H.; Zhao, M.; Lu, Q. Meta-analysis of differentially expressed microRNAs in systemic sclerosis. Int. J. Rheum. Dis. 2020, 23, 1297–1304. [Google Scholar] [CrossRef]
  9. Shichiri, M.; Ishimaru, S.; Ota, T.; Nishikawa, T.; Isogai, T.; Hirata, Y. Salusins: Newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat. Med. 2003, 9, 1166–1172. [Google Scholar] [CrossRef]
  10. Sato, K.; Watanabe, R.; Itoh, F.; Shichiri, M.; Watanabe, T. Salusins: Potential use as a biomarker for atherosclerotic cardiovascular diseases. Int. J. Hypertens. 2013, 2013, 965140. [Google Scholar] [CrossRef] [Green Version]
  11. Esfahani, M.; Saidijam, M.; Goodarzi, M.T.; Movahedian, A.; Najafi, R. Salusin-α attenuates inflammatory responses in vascular endothelial cells. Biochem. Mosc. 2017, 82, 1314–1323. [Google Scholar] [CrossRef]
  12. Sun, H.-J.; Zhao, M.-X.; Liu, T.-Y.; Ren, X.-S.; Chen, Q.; Li, Y.-H.; Kang, Y.-M.; Zhu, G.-Q. Salusin-β induces foam cell formation and monocyte adhesion in human vascular smooth muscle cells via miR155/NOX2/NFκB pathway. Sci. Rep. 2016, 6, 23596. [Google Scholar] [CrossRef] [Green Version]
  13. Sun, H.-J.; Liu, T.-Y.; Zhang, F.; Xiong, X.-Q.; Wang, J.-J.; Chen, Q.; Li, Y.-H.; Kang, Y.-M.; Zhou, Y.-B.; Han, Y.; et al. Salusin-β contributes to vascular remodeling associated with hypertension via promoting vascular smooth muscle cell proliferation and vascular fibrosis. Biochim. Biophys. Acta BBA -Mol. Basis Dis. 2015, 1852, 1709–1718. [Google Scholar] [CrossRef] [Green Version]
  14. Zhou, C.-H.; Liu, L.; Liu, L.; Zhang, M.-X.; Guo, H.; Pan, J.; Yin, X.-X.; Ma, T.-F.; Wu, Y.-Q. Salusin-β not salusin-α promotes vascular inflammation in ApoE-deficient mice via the I-κBα/NF-κB pathway. PLoS ONE 2014, 9, e91468. [Google Scholar] [CrossRef] [Green Version]
  15. Koya, T.; Miyazaki, T.; Watanabe, T.; Shichiri, M.; Atsumi, T.; Kim-Kaneyama, J.; Miyazaki, A. Salusin-β accelerates inflammatory responses in vascular endothelial cells via NF-κB signaling in LDL receptor-deficient mice in vivo and HUVECs in vitro. Am. J. Physiol.-Heart Circ. Physiol. 2012, 303, H96–H105. [Google Scholar] [CrossRef]
  16. Ren, X.-S.; Ling, L.; Zhou, B.; Han, Y.; Zhou, Y.-B.; Chen, Q.; Li, Y.-H.; Kang, Y.-M.; Zhu, G.-Q. Silencing salusin-β attenuates cardiovascular remodeling and hypertension in spontaneously hypertensive rats. Sci. Rep. 2017, 7, 43259. [Google Scholar] [CrossRef] [Green Version]
  17. Bhattacharjee, D.; Mondal, S.; Saha, A.; Misra, S.; Chatterjee, S.; Rao, A.; Sarkar, A.; Chatterjee, S.; Sinhamahapatra, P.; Ghosh, A. Effect of vasodilator and immunosuppressive therapy on the endothelial dysfunction in patients with systemic sclerosis. Clin. Exp. Med. 2022. [Google Scholar] [CrossRef]
  18. Cardillo, C.; Kilcoyne, C.M.; Cannon, R.O.; Panza, J.A. Interactions Between Nitric Oxide and Endothelin in the Regulation of Vascular Tone of Human Resistance Vessels In Vivo. Hypertension 2000, 35, 1237–1241. [Google Scholar] [CrossRef] [Green Version]
  19. Lerman, A.; Zeiher, A.M. Endothelial function: Cardiac events. Circulation 2005, 111, 363–368. [Google Scholar] [CrossRef]
  20. Sun, S.; Zhang, F.; Pan, Y.; Xu, Y.; Chen, A.; Wang, J.; Tang, H.; Han, Y. A TOR2A Gene Product: Salusin-β Contributes to Attenuated Vasodilatation of Spontaneously Hypertensive Rats. Cardiovasc. Drugs Ther. 2021, 35, 125–139. [Google Scholar] [CrossRef]
  21. Li, H.-B.; Qin, D.-N.; Cheng, K.; Su, Q.; Miao, Y.-W.; Guo, J.; Zhang, M.; Zhu, G.-Q.; Kang, Y.-M. Central blockade of salusin β attenuates hypertension and hypothalamic inflammation in spontaneously hypertensive rats. Sci. Rep. 2015, 5, 11162. [Google Scholar] [CrossRef] [Green Version]
  22. Xu, T.; Zhang, Z.; Liu, T.; Zhang, W.; Liu, J.; Wang, W.; Wang, J. Salusin-β contributes to vascular inflammation associated with pulmonary arterial hypertension in rats. J. Thorac. Cardiovasc. Surg. 2016, 152, 1177–1187. [Google Scholar] [CrossRef] [Green Version]
  23. Watanabe, T.; Suguro, T.; Sato, K.; Koyama, T.; Nagashima, M.; Kodate, S.; Hirano, T.; Adachi, M.; Shichiri, M.; Miyazaki, A. Serum salusin-α levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens. Res. 2008, 31, 463–468. [Google Scholar] [CrossRef] [Green Version]
  24. Zhou, C.-H.; Pan, J.; Huang, H.; Zhu, Y.; Zhang, M.; Liu, L.; Wu, Y. Salusin-β, but Not Salusin-α, Promotes Human Umbilical Vein Endothelial Cell Inflammation via the p38 MAPK/JNK-NF-κB Pathway. PLoS ONE 2014, 9, e107555. [Google Scholar] [CrossRef] [Green Version]
  25. Gao, S.; Xu, L.; Zhang, Y.; Yu, Q.; Li, J.; Guan, H.; Wang, X.; Cheng, D.; Liu, Y.; Bai, L.; et al. Salusin-α Inhibits Proliferation and Migration of Vascular Smooth Muscle Cell via Akt/mTOR Signaling. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2018, 50, 1740–1753. [Google Scholar] [CrossRef]
  26. von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P. STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet Lond. Engl. 2007, 370, 1453–1457. [Google Scholar] [CrossRef] [Green Version]
  27. Krasowska, D.; Rudnicka, L.; Dańczak-Pazdrowska, A.; Chodorowska, G.; Woźniacka, A.; Lis-Święty, A.; Czuwara, J.; Maj, J.; Majewski, S.; Sysa-Jędrzejowska, A.; et al. Systemic sclerosis—Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: Treatment. Dermatol. Rev. Dermatol. 2017, 104, 583–596. [Google Scholar] [CrossRef] [Green Version]
  28. Inker, L.A.; Eneanya, N.D.; Coresh, J.; Tighiouart, H.; Wang, D.; Sang, Y.; Crews, D.C.; Doria, A.; Estrella, M.M.; Froissart, M.; et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N. Engl. J. Med. 2021, 385, 1737–1749. [Google Scholar] [CrossRef]
  29. Delgado, C.; Baweja, M.; Crews, D.C.; Eneanya, N.D.; Gadegbeku, C.A.; Inker, L.A.; Mendu, M.L.; Miller, W.G.; Moxey-Mims, M.M.; Roberts, G.V.; et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2022, 79, 268–288. [Google Scholar] [CrossRef]
  30. Khanna, D.; Furst, D.E.; Clements, P.J.; Allanore, Y.; Baron, M.; Czirjak, L.; Distler, O.; Foeldvari, I.; Kuwana, M.; Matucci-Cerinic, M.; et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J. Scleroderma Relat. Disord. 2017, 2, 11–18. [Google Scholar] [CrossRef] [Green Version]
  31. Revelle, W. psych: Procedures for Psychological, Psychometric, and Personality Research (Version 2.2.9). 2022. Available online: https://CRAN.R-project.org/package=psych (accessed on 15 December 2022).
  32. Epskamp, S.; Costantini, G.; Haslbeck, J.; Isvoranu, A.; Cramer, A.O.J.; Waldorp, L.J.; Schmittmann, V.D.; Borsboom, D. qgraph: Graph Plotting Methods, Psychometric Data Visualization and Graphical Model Estimation (Version 1.9.3). 2022. Available online: https://CRAN.R-project.org/package=qgraph (accessed on 15 December 2022).
  33. Seol, H. Seolmatrix. 2022. Available online: https://github.com/hyunsooseol/seolmatrix (accessed on 15 December 2022).
  34. Kim, S. ppcor: Partial and Semi-Partial (Part) Correlation (Version 1.1). 2015. Available online: https://CRAN.R-project.org/package=ppcor (accessed on 15 December 2022).
  35. The Jamovi Project Jamovi (Version 2.3). 2022. Available online: https://www.jamovi.org (accessed on 15 December 2022).
  36. R Core Team. R: A Language and Environment for Statistical Computing (Version 4.1). 2021. Available online: https://www.R-project.org/ (accessed on 15 December 2022).
  37. Kimoto, S.; Sato, K.; Watanabe, T.; Suguro, T.; Koyama, T.; Shichiri, M. Serum levels and urinary excretion of salusin-α in renal insufficiency. Regul. Pept. 2010, 162, 129–132. [Google Scholar] [CrossRef]
  38. Watanabe, T.; Nishio, K.; Kanome, T.; Matsuyama, T.; Koba, S.; Sakai, T.; Sato, K.; Hongo, S.; Nose, K.; Ota, H.; et al. Impact of salusin-alpha and -beta on human macrophage foam cell formation and coronary atherosclerosis. Circulation 2008, 117, 638–648. [Google Scholar] [CrossRef] [Green Version]
  39. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J. 2021, 42, 2439–2454. [Google Scholar] [CrossRef]
  40. Yılmaz, E.; Kurt, D.; Aydın, E.; Çamcı, S.; Vural, A. A New Marker for Determining Cardiovascular Risk: Salusin Alpha. Cureus 2022, 14, e30340. [Google Scholar] [CrossRef]
  41. Koca, S.S.; Ozgen, M.; Isik, B.; Dagli, M.N.; Ustundag, B.; Isik, A. Serum salusin-α levels in systemic lupus erythematosus and systemic sclerosis. Eur. J. Rheumatol. 2014, 1, 14–17. [Google Scholar] [CrossRef]
  42. Erden, I.; Uçak, H.; Demir, B.; Cicek, D.; Bakar Dertlioğlu, S.; Oztürk, S.; Aydin, S. Serum salusin-α and salusin-β levels in patients with psoriasis. Eur. J. Dermatol. 2015, 25, 352–353. [Google Scholar] [CrossRef]
  43. Erden, I.; Demir, B.; Uçak, H.; Cicek, D.; Dertlioğlu, S.B.; Aydin, S. Serum salusin-α and salusin-β levels in patients with Behcet’s disease. Eur. J. Dermatol. 2014, 24, 577–582. [Google Scholar] [CrossRef]
  44. Ozgen, M.; Koca, S.S.; Dagli, N.; Balin, M.; Ustundag, B.; Isik, A. Serum salusin-alpha level in rheumatoid arthritis. Regul. Pept. 2011, 167, 125–128. [Google Scholar] [CrossRef]
  45. Kobak, S.; Atabay, T.; Akyildiz, M.; Gokduman, A.; Vural, H. Serum salusin-α and salusin-β levels in patients with psoriatic arthritis. Reumatologia 2022, 60, 306–310. [Google Scholar] [CrossRef]
  46. Cinoku, I.I.; Mavragani, C.P.; Moutsopoulos, H.M. Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity. Eur. J. Clin. Investig. 2020, 50, e13195. [Google Scholar] [CrossRef] [Green Version]
  47. Marks, J.L.; Edwards, C.J. Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Ther. Adv. Musculoskelet. Dis. 2012, 4, 149–157. [Google Scholar] [CrossRef]
  48. Bălănescu, A.-R.; Bojincă, V.C.; Bojincă, M.; Donisan, T.; Bălănescu, S.M. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. Exp. Ther. Med. 2019, 17, 1024–1029. [Google Scholar] [CrossRef] [Green Version]
  49. Mangoni, A.A.; Zinellu, A.; Sotgia, S.; Carru, C.; Piga, M.; Erre, G.L. Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence. Mediators Inflamm. 2017, 2017, 9632846. [Google Scholar] [CrossRef] [Green Version]
  50. Liu, D.; Lv, H.; Liu, Q.; Sun, Y.; Hou, S.; Zhang, L.; Yang, M.; Han, B.; wang, G.; Wang, X.; et al. Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow. J. Transl. Med. 2019, 17, 378. [Google Scholar] [CrossRef] [Green Version]
  51. Yang, D.; Haemmig, S.; Zhou, H.; Pérez-Cremades, D.; Sun, X.; Chen, L.; Li, J.; Haneo-Mejia, J.; Yang, T.; Hollan, I.; et al. Methotrexate attenuates vascular inflammation through an adenosine-microRNA-dependent pathway. eLife 2021, 10, e58064. [Google Scholar] [CrossRef]
  52. Riksen, N.P.; Barrera, P.; van den Broek, P.H.H.; van Riel, P.L.C.M.; Smits, P.; Rongen, G.A. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann. Rheum. Dis. 2006, 65, 465–470. [Google Scholar] [CrossRef] [Green Version]
  53. Verhoeven, F.; Prati, C.; Chouk, M.; Demougeot, C.; Wendling, D. Methotrexate and cardiovascular risk in rheumatic diseases: A comprehensive review. Expert Rev. Clin. Pharmacol. 2021, 14, 1105–1112. [Google Scholar] [CrossRef]
  54. Kim, H.-J.; Kim, M.-J.; Lee, C.-K.; Hong, Y.-H. Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis. J. Korean Med. Sci. 2015, 30, 1589–1596. [Google Scholar] [CrossRef] [Green Version]
  55. Plein, S.; Erhayiem, B.; Fent, G.; Horton, S.; Dumitru, R.B.; Andrews, J.; Greenwood, J.P.; Emery, P.; Hensor, E.M.; Baxter, P.; et al. Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. Ann. Rheum. Dis. 2020, 79, 1414–1422. [Google Scholar] [CrossRef]
  56. Turiel, M.; Tomasoni, L.; Sitia, S.; Cicala, S.; Gianturco, L.; Ricci, C.; Atzeni, F.; De Gennaro Colonna, V.; Longhi, M.; Sarzi-Puttini, P. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc. Ther. 2010, 28, e53–e64. [Google Scholar] [CrossRef]
  57. van Leuven, S.I.; Kastelein, J.J.P.; Allison, A.C.; Hayden, M.R.; Stroes, E.S.G. Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles? Cardiovasc. Res. 2006, 69, 341–347. [Google Scholar] [CrossRef] [PubMed]
  58. Olejarz, W.; Bryk, D.; Zapolska-Downar, D.; Małecki, M.; Stachurska, A.; Sitkiewicz, D. Mycophenolic acid attenuates the tumour necrosis factor-α-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-κB and ROS pathways. Eur. J. Clin. Investig. 2014, 44, 54–64. [Google Scholar] [CrossRef]
  59. Miljkovic, D.; Cvetkovic, I.; Stosic-Grujicic, S.; Trajkovic, V. Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts. Clin. Exp. Immunol. 2003, 132, 239–246. [Google Scholar] [CrossRef] [PubMed]
  60. Senda, M.; DeLustro, B.; Eugui, E.; Natsumeda, Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995, 60, 1143–1148. [Google Scholar] [CrossRef] [PubMed]
  61. Koo, T.Y.; Kim, Y.J.; Yang, W.S.; Park, J.S.; Han, N.J.; Lee, J.M.; Park, S.K. Mycophenolic acid regulates spleen tyrosine kinase to repress tumour necrosis factor-alpha-induced monocyte chemotatic protein-1 production in cultured human aortic endothelial cells. Cell Biol. Int. 2013, 37, 19–28. [Google Scholar] [CrossRef] [PubMed]
  62. Kiani, A.N.; Magder, L.S.; Petri, M. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol. Int. 2012, 32, 2701–2705. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Sato-Okabayashi, Y.; Isoda, K.; Heissig, B.; Kadoguchi, T.; Akita, K.; Kitamura, K.; Shimada, K.; Hattori, K.; Daida, H. Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis. Int. J. Cardiol. Heart Vasc. 2020, 28, 100529. [Google Scholar] [CrossRef]
  64. Watanabe, T.; Sato, K.; Itoh, F.; Iso, Y.; Nagashima, M.; Hirano, T.; Shichiri, M. The roles of salusins in atherosclerosis and related cardiovascular diseases. J. Am. Soc. Hypertens. JASH 2011, 5, 359–365. [Google Scholar] [CrossRef]
Diagnostics 13 00848 g001 550
Figure 1. Salusin-α concentrations [pg/mL] in the experimental and control groups (U = 350.5; p = 0.004).
Figure 1. Salusin-α concentrations [pg/mL] in the experimental and control groups (U = 350.5; p = 0.004).
Diagnostics 13 00848 g001
Diagnostics 13 00848 g002 550
Figure 2. Simple linear correlation between salusin-α and β concentrations [pg/mL]. Statistically significant linear regression results were found. For all patients: F(1, 70) = 94.56; p < 0.001; R2 = 0.57, for the systemic sclerosis group: F(1, 45) = 54.81; p < 0.001; R2 = 0.55, for the healthy volunteers: F(1, 23) = 326.64; p < 0.001; R2 = 0.93.
Figure 2. Simple linear correlation between salusin-α and β concentrations [pg/mL]. Statistically significant linear regression results were found. For all patients: F(1, 70) = 94.56; p < 0.001; R2 = 0.57, for the systemic sclerosis group: F(1, 45) = 54.81; p < 0.001; R2 = 0.55, for the healthy volunteers: F(1, 23) = 326.64; p < 0.001; R2 = 0.93.
Diagnostics 13 00848 g002
Diagnostics 13 00848 g003 550
Figure 3. Gaussian graphical model for continuous variables evaluated in the experimental group. Legend: crea—serum creatinine concentration; DLCO—diffusion lung capacity for carbon monoxide; time—disease duration; eGFR—estimated glomerular filtration rate; LYM—lymphocyte percentage; mRSS—modified Rodnan scale score; NLR—neutrophil to lymphocyte ratio; NEU—neutrophils percentage; Sal α—serum salusin-α; Sal β—serum salusin-β. Green color—positive partial correlation; red color—negative partial correlation; thickness of the line reflects the strength of the correlation.
Figure 3. Gaussian graphical model for continuous variables evaluated in the experimental group. Legend: crea—serum creatinine concentration; DLCO—diffusion lung capacity for carbon monoxide; time—disease duration; eGFR—estimated glomerular filtration rate; LYM—lymphocyte percentage; mRSS—modified Rodnan scale score; NLR—neutrophil to lymphocyte ratio; NEU—neutrophils percentage; Sal α—serum salusin-α; Sal β—serum salusin-β. Green color—positive partial correlation; red color—negative partial correlation; thickness of the line reflects the strength of the correlation.
Diagnostics 13 00848 g003
Diagnostics 13 00848 g004 550
Figure 4. Association between serum salusin-α levels [pg/mL] and therapy used (U = 176.0; p = 0.026).
Figure 4. Association between serum salusin-α levels [pg/mL] and therapy used (U = 176.0; p = 0.026).
Diagnostics 13 00848 g004
Table
Table 1. Demographic, clinical, and laboratory results of patients in the experimental group.
Table 1. Demographic, clinical, and laboratory results of patients in the experimental group.
VariablePatients with Systemic Sclerosis
(N = 48)
women, n, %44 (92%)
age, years56.4 (11.4)
BMI, kg/m224.9 (4.1)
duration of disease since the first diagnosis, years6.5 [1–38]
serum creatinine, mg/dl0.73 [0.48–1.06]
CKD-EPI eGFR, mL/min/1.73 m292.78 (16.88)
mRSS6 [2–22]
DLCO, n, %71.1 [36.0–135.6]
neutrophiles, n, %63.6 (8.7)
lymphocytes, n, %25.2 (7.6)
NLR2.63 [0.94–6.69]
coronary artery disease, n, %7 (15%) *
hyper- or hypothyroidism, n, %11 (23%)
arterial hypertension, n, %17 (35%)
gastroesophageal reflux disease, n, %11 (23%) *
another autoimmune disease, n, %11 (23%) *
dyslipidemia, n, %13 (30%) ᶧ
Scl-70 antibodies, n, %23 (49%) *
ACA antibodies, n, %19 (40%) *
immunosuppressive treatment, n, %27 (57%) *
Legend: BMI—body mass index; CKD-EPI eGFR—estimated glomerular filtration rate calculated with the Chronic Kidney Disease Epidemiology Collaboration (2021 update) equation; DLCO—diffusing capacity of the lung for carbon monoxide; NLR—neutrophil to lymphocyte ratio; mRSS—modified Rodnan scale score. Results are reported as median [range] or mean (standard deviation), as appropriate. *—missing data in one patient. ᶧ—missing data in five patients.
Table
Table 2. Salusin concentrations in the studied groups.
Table 2. Salusin concentrations in the studied groups.
SalusinPatients with Systemic Sclerosis
(N = 48)		Healthy Volunteers
(N = 25)		Test Statistic and p Value
salusin-α, pg/mL, median [range]181.85
[85.66–951.80]		120.70
[24.03–362.40]		U = 350.5, p = 0.004
salusin-β, pg/mL, median [range]173.70
[113.70–3288.00]		186.30
[120.30–773.50]		U = 550.0, p = 0.662
Table
Table 3. Correlations or associations between parameters reflecting skin or internal organ involvement in systemic sclerosis and salusins concentrations.
Table 3. Correlations or associations between parameters reflecting skin or internal organ involvement in systemic sclerosis and salusins concentrations.
Organ/SystemVariableFor Salusin-αFor Salusin-β
Test Statistic/Correlation Coefficientp ValueTest Statistic/Correlation Coefficientp Value
skinmRSSρ = −0.050.772ρ = −0.120.474
fingertip ulcerationsU = 71.00.101U = 65.00.150
cardiovascularRaynaud’s phenomenonU = 228.50.227U = 184.50.053
arterial hypertensionU = 244.50.690U = 242.00.782
coronary artery diseaseU = 112.50.420U = 115.00.521
pulmonarylung fibrosis in HRCTU = 92.00.724U = 99.00.986
DLCOρ = 0.120.561ρ = 0.220.305
gastrointestinalesophageal dysmotility
in X-ray with contrast		U = 65.50.461U = 54.50.267
gastroesophageal refluxU = 194.00.930U = 183.50.725
renalserum creatinineρ = −0.320.035ρ = −0.370.015
Legend: DLCO—diffusing capacity of the lung for carbon monoxide; HRCT—high-resolution computed tomography; mRSS—modified Rodnan scale score; ρ—Spearman’s rank correlation coefficient.
Table
Table 4. Salusin-α concentrations in the experimental group—patients treated with either vasodilators only or with vasodilators in combination with immunosuppressive agents.
Table 4. Salusin-α concentrations in the experimental group—patients treated with either vasodilators only or with vasodilators in combination with immunosuppressive agents.
No Immunosuppression
(N = 17), pg/mL, Median [Range]		With Immunosuppression
(N = 27), pg/mL, Median [Range]		Test Statistic and p Value
174.50
[85.66–525.10]		235.30
[133.50–951.80]		U = 176.0,
p = 0.026
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Nowaczyk, J.; Blicharz, L.; Zawistowski, M.; Sikora, M.; Zaremba, M.; Czuwara, J.; Rudnicka, L. The Clinical Significance of Salusins in Systemic Sclerosis—A Cross-Sectional Study. Diagnostics 2023, 13, 848. https://doi.org/10.3390/diagnostics13050848

AMA Style

Nowaczyk J, Blicharz L, Zawistowski M, Sikora M, Zaremba M, Czuwara J, Rudnicka L. The Clinical Significance of Salusins in Systemic Sclerosis—A Cross-Sectional Study. Diagnostics. 2023; 13(5):848. https://doi.org/10.3390/diagnostics13050848

Chicago/Turabian Style

Nowaczyk, Joanna, Leszek Blicharz, Michał Zawistowski, Mariusz Sikora, Michał Zaremba, Joanna Czuwara, and Lidia Rudnicka. 2023. "The Clinical Significance of Salusins in Systemic Sclerosis—A Cross-Sectional Study" Diagnostics 13, no. 5: 848. https://doi.org/10.3390/diagnostics13050848

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop